S. C. Armstrong, Protein kinase activation and myocardial ischemia/ reperfusion injury, Cardiovascular Research, vol.61, issue.3, pp.427-436, 2004.

G. Calcagni, R. Adorisio, S. Martinelli, G. Grutter, A. Baban et al., Clinical presentation and natural history of hypertrophic cardiomyopathy in RASopathies, Heart Failure Clinics, vol.14, issue.2, pp.225-235, 2018.

J. Desvignes, M. Bartoli, V. Delague, M. Krahn, M. Miltgen et al., VarAFT: a variant annotation and filtration system for human next generation sequencing data, Nucleic Acids Research, vol.46, pp.545-553, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01852493

A. S. Dhillon, C. Pollock, H. Steen, P. E. Shaw, H. Mischak et al., Cyclic AMP-dependent kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259, Molecular and Cellular Biology, vol.22, issue.10, pp.3237-3246, 2002.

B. Ezquieta, J. L. Santomé, A. Carcavilla, E. Guillén-navarro, A. Pérez-aytés et al., Alterations in RAS-MAPK genes in 200 Spanish patients with Noonan and other neuro-cardio-facio-cutaneous syndromes. Genotype and cardiopathy, Revista Espanola De Cardiologia (English Ed.), vol.65, issue.5, pp.447-455, 2012.

B. D. Gelb, A. E. Roberts, and M. Tartaglia, Cardiomyopathies in Noonan syndrome and the other RASopathies, Progress in Pediatric Cardiology, vol.39, issue.1, pp.13-19, 2015.

F. Hakami, M. W. Dillon, M. Lebo, and H. Mason-suares, Retrospective study of prenatal ultrasound findings in newborns with a Noonan spectrum disorder: prenatal diagnosis of Noonan spectrum disorders, Prenatal Diagnosis, vol.36, issue.5, pp.418-423, 2016.

E. J. Hickey, R. Mehta, M. Elmi, K. Asoh, B. W. Mccrindle et al., Survival implications: hypertrophic cardiomyopathy in Noonan syndrome, Congenital Heart Disease, vol.6, issue.1, pp.41-47, 2011.

R. K. Hopper, J. A. Feinstein, M. A. Manning, W. Benitz, and L. Hudgins, Neonatal pulmonary arterial hypertension and Noonan syndrome: two fatal cases with a specific RAF1 mutation, American Journal of Medical Genetics. Part A, vol.167, issue.4, pp.882-885, 2015.

J. M. Ko, J. Kim, G. Kim, and H. Yoo, PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome, Journal of Human Genetics, vol.53, pp.999-1006, 2008.

T. Kobayashi, Y. Aoki, T. Niihori, H. Cavé, A. Verloes et al., Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation, Human Mutation, vol.31, issue.3, pp.284-294, 2010.

V. Kuburovi?, V. Vukomanovi?, A. Carcavilla, B. Ezquieta-zubicaray, and N. Kuburovi?, Two cases of LEOPARD syndrome--RAF1 mutations firstly described in children, The Turkish Journal of Pediatrics, vol.53, issue.6, pp.687-691, 2011.

B. H. Lee, J. Kim, H. Y. Jin, G. Kim, J. Choi et al., Spectrum of mutations in Noonan syndrome and their correlation with phenotypes, The Journal of Pediatrics, vol.159, issue.6, pp.1029-1035, 2011.

G. Limongelli, L. Hawkes, R. Calabro, W. J. Mckenna, and P. Syrris, Mutation screening of the PTPN11 gene in hypertrophic cardiomyopathy, European Journal of Medical Genetics, vol.49, issue.5, pp.426-430, 2006.

A. M. Nystrom, S. Ekvall, E. Berglund, M. Björkqvist, G. Braathen et al., Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders, Journal of Medical Genetics, vol.45, issue.8, pp.500-506, 2008.

B. Pandit, A. Sarkozy, L. A. Pennacchio, C. Carta, K. Oishi et al., Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy, Nature Genetics, vol.39, issue.8, pp.1007-1012, 2007.

T. W. Prendiville, K. Gauvreau, E. Tworog-dube, L. Patkin, R. S. Kucherlapati et al., Cardiovascular disease in Noonan syndrome, Archives of Disease in Childhood, vol.99, issue.7, pp.629-634, 2014.

M. A. Razzaque, T. Nishizawa, Y. Komoike, H. Yagi, M. Furutani et al., Germline gain-of-function mutations in RAF1 cause Noonan syndrome, Nature Genetics, vol.39, issue.8, pp.1013-1017, 2007.

A. Rohini, N. Agrawal, C. N. Koyani, and R. Singh, Molecular targets and regulators of cardiac hypertrophy, Pharmacological Research, vol.61, issue.4, pp.269-280, 2010.

V. Sala, S. Gallo, C. Leo, S. Gatti, G. Bd et al., Signaling to cardiac hypertrophy: insights from human and mouse RASopathies, Molecular Medicine, vol.18, issue.1, pp.938-947, 2012.

M. E. Sana, A. Spitaleri, D. Spiliotopoulos, L. Pezzoli, L. Preda et al., Identification of a novel de novo deletion in RAF1 associated with biventricular hypertrophy in Noonan syndrome, American Journal of Medical Genetics. Part A, vol.164, issue.8, pp.2069-2073, 2014.

M. Tartaglia, G. Bd, and M. Zenker, Noonan syndrome and clinically related disorders, Best Practice & Research Clinical Endocrinology & Metabolism, vol.25, issue.1, pp.161-179, 2011.

D. Thompson, J. Patrick-esteve, J. W. Surcouf, D. Rivera, B. Castellanos et al., RAF1 variants causing biventricular hypertrophic cardiomyopathy in two preterm infants: further phenotypic delineation and review of literature, Clinical Dysmorphology, vol.26, issue.4, pp.195-199, 2017.

M. Tumurkhuu, M. Saitoh, A. Sato, K. Takahashi, M. Mimaki et al., Comprehensive genetic analysis of overlapping syndromes of RAS/RAF/MEK/ERK pathway: genetic analysis in RAS pathway syndromes, Pediatrics International, vol.52, issue.4, pp.557-562, 2010.

J. D. Wilkinson, A. M. Lowe, B. A. Salbert, L. A. Sleeper, S. D. Colan et al., Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry, American Heart Journal, vol.164, issue.3, pp.442-448, 2012.

, Genetics Research, vol.7

,

, Universite Mediterranee, on, 2020.